All In Biotech

Drug Trial Radar · NCT00332189

Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006

A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006

Last checked: Nov 20, 2026Latest source record: Nov 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Jul 2006

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jun 1, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety of long-term treatment with Phenoptin in subjects with phenylketonuria (PKU) who participated in Phase 3 clinical studies with Phenoptin.

Conditions

  • Phenylketonuria

Interventions

  • sapropterin dihydrochlorideDrug

    5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tabulation of the Incidence and Frequency of All AEs and SAEs That Occur Throughout the Study.Time frame: Baseline through Final Visit (a Maximum of 30 months) with AEs collected at month 3 and 6 then at 6 month intervals

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Jose, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Portland, Oregon

  • Site not named

    Dallas, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Seattle, Washington

  • Site not named

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.